Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO update 2016

ASCO update 2016 The past few years have seen major progress in cancer research and treatment. Today we are able to select treatments based on molecular profiling of tumors and do not solely rely on tumor type and stage. The most recent advance has taken place in the field of immunotherapy, and at this year’s ASCO again a huge number of studies were reported dealing with immunotherapy. In Europe we expect approval of different immunotherapies in various entities ranging from head and neck cancer, urothelial cancer, gastric cancer to lung cancer and colorectal cancer. But immunotherapy is not the only area of progress. There are tremendous advances in surgery, chemotherapy and targeted agents, too, as will be discussed in further detail in this report of the most important abstracts of this year’s ASCO by our experts in the field Drs. Wöll, Bartsch, Pall, Roider-Schur, Hamacher, Brodowicz, Kacirek, and myself. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASCO update 2016

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/asco-update-2016-SmlpPCBf0r
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0301-5
Publisher site
See Article on Publisher Site

Abstract

The past few years have seen major progress in cancer research and treatment. Today we are able to select treatments based on molecular profiling of tumors and do not solely rely on tumor type and stage. The most recent advance has taken place in the field of immunotherapy, and at this year’s ASCO again a huge number of studies were reported dealing with immunotherapy. In Europe we expect approval of different immunotherapies in various entities ranging from head and neck cancer, urothelial cancer, gastric cancer to lung cancer and colorectal cancer. But immunotherapy is not the only area of progress. There are tremendous advances in surgery, chemotherapy and targeted agents, too, as will be discussed in further detail in this report of the most important abstracts of this year’s ASCO by our experts in the field Drs. Wöll, Bartsch, Pall, Roider-Schur, Hamacher, Brodowicz, Kacirek, and myself.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Dec 7, 2016

References

  • A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study
    Verheij, M; Jansen, EPM; Cats, A
  • A randomized, open label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC)
    Kang, Y-H; Shah, MA; Ohtsu, A
  • CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)
    Janjigian, YY; Bendell, JC; Calvo Eet
  • PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breats cancer (ABC)
    Finn, RS; Martin, M; Hope, S
  • An open-label phase II trial of dabrafenib (D) in combination with rametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
    Planchard, D; Besse, B; Groen, HJM
  • Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+NSCLC): primary results from the J‑ALEX study
    Nokihara, H; Hida, T; Kondo, M
  • Activity of Regorafenib in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): results of a double-blind, randomized placebo (PL) controlled phase II trial
    Mir, O; Brodowicz, T; Wallet, J
  • Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CAGB/SWOG 80405 (Alliance)
    Vennok, AP; Niedzwiecki, D; Innocenti, F